ZEGFROVY® (Sunvozertinib)

The FDA on July 2, 2025, granted accelerated approval to ZEGFROVY® for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ZEGFROVY® is a product of Dizal (Jiangsu) Pharmaceutical Co., Ltd.